Trauner, Michael

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 1,131

Bile salt transporters: molecular characterization, function, and regulation

Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 999

Gut-liver axis: Pathophysiological concepts and clinical implications

Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism

Gut microbiota and healthLiver Disease and Transplantation

Cited by 843

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 757

Bile acid receptors as targets for drug development

Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 696

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology

Liver Disease Diagnosis and TreatmentDrug Transport and Resistance Mechanisms

Cited by 634

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 576

Recent insights into the pathogenesis of nonalcoholic fatty liver disease

Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 573

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 556

New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond

Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 537

Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis

Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 533

Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology

Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 490

EASL Clinical Practice Guidelines on sclerosing cholangitis

Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 419

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice†

Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology

Drug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

Cited by 355

Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation

Angelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology

Gut microbiota and healthInflammatory Bowel Disease

Cited by 330

Current treatment of non‐alcoholic fatty liver disease

Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 305

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 297

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., et al. (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 277

Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis

Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 275

The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells

Bruschi, F. V., Claudel, T., Tardelli, M., Caligiuri, A., Stulnig, T. M., Marra, F., & Trauner, M. (2017) · Hepatology

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 268

Nuclear Receptors in Liver Disease Δ

Wagner, M., Zollner, G., & Trauner, M. (2011) · Hepatology

Liver physiology and pathologyDrug Transport and Resistance Mechanisms

Cited by 260

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 227

Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH

Hendrikx, T., Porsch, F., Kiss, M. G., Rajcic, D., Papac-Miličević, N., Hoebinger, C., Goederle, L., Hladik, A., Shaw, L. E., Horstmann, H., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 220